12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga · 07/25 21:06
Gainers
- Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $4.33 during Friday's after-market session. The market value of their outstanding shares is at $147.4 million.
- Ekso Bionics Holdings (NASDAQ:EKSO) shares increased by 7.88% to $5.2. The company's market cap stands at $11.1 million.
- Insight Molecular (NASDAQ:IMDX) shares rose 5.7% to $3.05. The market value of their outstanding shares is at $84.6 million.
- Akso Health (NASDAQ:AHG) shares increased by 5.0% to $2.1. The market value of their outstanding shares is at $701.9 million.
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock moved upwards by 4.97% to $27.64. The company's market cap stands at $1.9 billion.
- Ernexa Therapeutics (NASDAQ:ERNA) shares increased by 4.61% to $2.04. The company's market cap stands at $15.4 million.
Losers
- Calidi Biotherapeutics (AMEX:CLDI) shares fell 13.1% to $0.63 during Friday's after-market session. The company's market cap stands at $26.6 million.
- Healthcare Triangle (NASDAQ:HCTI) stock decreased by 8.76% to $0.06. The company's market cap stands at $22.1 million.
- Reshape Lifesciences (NASDAQ:RSLS) stock declined by 6.46% to $2.32. The company's market cap stands at $6.5 million.
- Aptorum Group (NASDAQ:APM) shares decreased by 5.53% to $1.71. The market value of their outstanding shares is at $12.5 million.
- HCW Biologics (NASDAQ:HCWB) stock decreased by 5.4% to $4.03. The company's market cap stands at $8.8 million.
- Onconetix (NASDAQ:ONCO) stock decreased by 5.26% to $3.97. The market value of their outstanding shares is at $1.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.